



Notice Regarding Selection for AMED Public Offering Project:

"Development of Infrastructure Technology for the Industrialization of Regenerative Medicine and Gene Therapy"

(Project Title: Development of a Novel GPC-1 CAR-T Therapy for GPC-1 Positive Recurrent and Refractory Solid Tumors)

April 2, 2026

1. Overview

As announced on December 10, 2024, REPROCELL's project, "Development of a Novel GPC-1 CAR-T Therapy for GPC-1 Positive Recurrent and Refractory Solid Tumors" (hereinafter the "Project"), was selected for the "FY2026 Development of Infrastructure Technology for the Industrialization of Regenerative Medicine and Gene Therapy" project, a public offering by the Japan Agency for Medical Research and Development (AMED).

We are pleased to announce that the Project has been selected for continued support in fiscal year 2026.

2. Period of the Subsidized Project and Grant Amount (Planned)

- **Subsidized Project Period:** April 1, 2026, to March 31, 2027
- **FY2026 Grant Amount (Planned):** 59,900 thousand yen

The final grant amount and the timing of its recognition will be determined upon receipt of the official "Notice of Grant Decision" from AMED.

3. Impact on Financial Results

The finalized grant amount is expected to be determined in the next fiscal year; therefore, an announcement will be made promptly once the amount is fixed. Furthermore, this matter will have no impact on the Company's consolidated financial results for the fiscal year ending March 31, 2027.